Isolates BR3 and BR4, which are identified as
P. terrae and
M. morganii, respectively, may be described as opportunistic pathogens and may be assigned to risk group II (moderate individual risk, limited community risk, and includes opportunistic pathogens)
[16] in the light of earlier studies, where
Proteus and
Morganella, both bacterial genera, were revealed to cause skin wounds and urinary tract infections
[12][13][17][18]. Additionally,
M. morganii is an unusual opportunistic pathogen and results in a high mortality rate due to its virulence and increasing drug resistance
[12][18], which corroborated the researchers' study that BR4 was found here to be resistant to the antibiotics ampicillin and vancomycin, thus adding to the pathogenic status of BR4. Out of seven of the reported species of
Proteus, three species,
myxofaciens,
terrae, and
cibarius, have no report of pathogenicity for humans
[13][19][20]. Thus, the clustering of BR3 with
P. terrae N5/687(T) revealed that isolate BR3 is a non-pathogenic bacterium. Although BR3 is resistant to some tested antibiotics, such as ampicillin, vancomycin, and tetracycline, it is sensitive to other tested antibiotics, such as kanamycin, gentamicin, and chloramphenicol. Thus, BR3 may be characterized as either non-pathogenic to humans or as an opportunistic pathogen causing mild infections of the skin or urinary tract. High EtBr bio-degradation efficiency
[10], sensitivity to readily available antimicrobials and its mild severity or non-pathogenicity to humans
[13][19][20], makes BR3 a suitable isolate for its use in industrial applications, when the utmost care is taken. On the other hand, the authors discourage the application of BR4 in EtBr biodegradation on an industrial scale, as it is an inefficient bio-degrader
[10] with a high pathogenic status and increasing drug-resistant report.